The PCSK9 inhibitor evolocumab (marketed as Repatha) significantly reduces the risk of first-time heart attacks and strokes in high-risk patients, according to the VESALIUS-CV trial presented at the American College of Cardiology's Annual Scientific Session and published simultaneously in JAMA.

The international Phase 3 trial enrolled 12,257 patients at high cardiovascular risk who had never experienced a heart attack or stroke. Over a median follow-up of 4.6 years, patients receiving evolocumab alongside standard therapy saw a 25% overall reduction in major cardiovascular events and a 36% reduction in heart attacks specifically. Mortality was also lower at 7.9% compared to 9.7% in the placebo group.

"The results of this trial offer hope for preventing a first heart attack, stroke, or other cardiovascular event in patients who are at high risk," said lead author Dr. Erin Bohula of Mass General Brigham. The findings are particularly significant for diabetic patients, where a subgroup of 3,655 participants showed a 31% reduction in cardiovascular events.